8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act

Date of Report:  April 29, 2011

(Date of Earliest Event Reported)

Akorn, Inc.

(Exact Name of Registrant as Specified in its Charter)

Louisiana	001-32360	72-0717400
(State or other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

1925 W. Field Court, Suite 300

Lake Forest, Illinois  60045

(Address of principal executive offices)

(847) 279-6100

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):

o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240. 13e-4(c))

Item 2.02        Results of Operations and Financial Condition

On May 3, 2011, Akorn issued a press release announcing financial results for the quarter ended March 31, 2011. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

The information furnished pursuant to Item 2.02 of this report, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, unless the Registrant expressly incorporates the information by reference in such a filing.

Item 5.07        Submission of Matters to a Vote of Security Holders

On April 29, 2011, Akorn held its annual meeting of shareholders.  At that meeting, by proxy vote, the shareholders of the Company voted affirmatively to elect six directors, to ratify the Audit Committee’s selection of Ernst & Young LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2011, to approve by non-binding advisory vote the Company’s current executive compensation programs and practices, and to advise that future votes on executive compensation should occur every one year.

1. Election of Directors.  The following six individuals were elected to serve as directors of the Company for a one-year term beginning immediately and ending on the date of the Company’s 2012 annual meeting of shareholders:

Nominee	Votes For	Votes Withheld	Broker Non Votes
John  N. Kapoor, Ph.D.	69,396,739	600,460	14,971,242
Kenneth S. Abramowitz	69,802,318	194,881	14,971,242
Ronald M. Johnson	67,681,330	2,315,869	14,971,242
Steven J. Meyer	69,615,124	382,075	14,971,242
Brian Tambi	69,799,135	198,064	14,971,242
Alan Weinstein	69,616,664	380,535	14,971,242

2. Ratification of Ernst & Young LLP to serve as our independent registered public accounting firm for the fiscal year ending December 31, 2011.  Ratification required affirmative vote of a majority of the votes cast.  Voting results were as follows:

	Shares Voted	Percent of Votes Cast
For	84,885,280	99.9%
Against	72,969	0.1%
Abstain	10,192	0.0%
Non Votes	0	n/a

3. Non-binding advisory vote to approve the Company’s current executive compensation programs and practices.  The advice of shareholders is based on the majority of votes cast, with abstentions and non-votes having no impact on the results.  Voting results were as follows:

	Shares Voted	Percent of Votes Cast
For	69,124,221	98.8%
Against	855,287	1.2%
Abstain	17,691	n/a
Non Votes	14,971,242	n/a

4. Non-binding advisory vote on the frequency with which the Company should hold future non-binding advisory votes on the Company’s executive compensation programs and practices.  The advice of shareholders is based on the majority of votes cast, with abstentions and non-votes having no impact on the results.  Voting results were as follows:

Frequency of Future Votes on Executive Compensation	Shares Voted	Percent of Votes Cast
Every One Year	66,653,207	95.3%
Every Two Years	15,161	0.0%
Every Three Years	3,295,547	4.7%
Abstain	33,284	n/a
Non-Votes	14,971,242	n/a

Item 7.01                      Regulation FD Disclosure.

On May 3, 2011, Akorn issued a press release announcing that it entered into an agreement to acquire Woburn, MA, based Advanced Vision Research, Inc., an over-the-counter ophthalmic company that develops and markets eye care products under the TheraTears® and MacuTrition ® brand names, for $26 million in cash on hand, and that it plans to launch a new Consumer Health Division. A copy of the press release is furnished as Exhibit 99.2 to this report and is incorporated herein by reference.

The information furnished pursuant to Item 7.01 of this report, including Exhibit 99.2, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, unless the Registrant expressly incorporates the information by reference in such a filing.

Item 9.01        Financial Statements and Exhibits.

(d) Exhibits. The following is furnished as an exhibit to this Current Report:

Exhibit No.	Description of Exhibit                                                                                               .
99.1	Press release issued by Akorn on May 3, 2011 announcing financial results for the quarter ended March 31, 2011.
99.2	Press release issued by Akorn on May 3, 2011 announcing entry into an agreement to acquire Vision Research, Inc. and plans to launch a new Consumer Health Division.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Akorn, Inc.

By: /s/  Timothy A. Dick                 

Timothy A. Dick

Chief Financial Officer

Date:  May 3, 2011

EX-99.1

Exhibit 99.1

Akorn Reports First Quarter 2011 Financial Results

-Revenues of $25.4 million & Adjusted EBITDA of $8.4 million-

-Raises Outlook for 2011-

LAKE FOREST, Ill.--(BUSINESS WIRE)--May 3, 2011--Akorn, Inc. (NASDAQ:AKRX), a niche generic pharmaceutical company, today reported financial results for the first quarter of 2011. The Company also separately announced it has entered into an agreement to acquire Advanced Vision Research, Inc. AVR is a leader in the over-the-counter dry eye market with annual sales of approximately $20.0 million in 2010, both domestic and international. AVR’s products are sold under the TheraTears® brand for use in the treatment of dry eye, eyelid cleansing, eye nutrition and contact lens comfort.

Raj Rai, Chief Executive Officer commented, “These are exciting times for Akorn. We are evaluating other acquisition opportunities that are complementary to our existing business. With the continued strength in our base business and the opportunities to grow through our internal R&D efforts, we feel optimistic about the long term growth prospects for our company.”

First Quarter Highlights

● Core business revenue growth of 66% over the comparable prior year quarter. Akorn’s core business consists of the ophthalmic, hospital drugs & injectables and contract services segments.

● Gross margins increased to 56%, up from 53% in the prior quarter and 41% in the comparable prior year quarter.

● Seventh consecutive quarter of core revenue, core gross margin and adjusted EBITDA growth.

● Filed three new internally developed ANDAs with a combined market value of $190 million.

● Successfully transitioned the Akorn-Strides joint venture to Pfizer.

Consolidated revenue for the first quarter of 2011 was $25.4 million, up 24% over the comparable prior year quarter consolidated revenue of $20.5 million. First quarter 2011 core business revenue was $25.4 million, up 66% over the comparable prior year quarter core revenue of $15.3 million. The increase in core business revenue was the result of the continued growth of products launched in 2010 as well as strong organic growth in established injectable and ophthalmic products.

Consolidated gross margin for the first quarter of 2011 was 56% compared to 41% in the comparable prior year period. Sustained improvements in gross margin are the result of favorable product mix, selected price increases, higher utilization of plant capacities and the launch of new, higher margin products in 2010.

Net income for the first quarter of 2011 was $5.8 million, and earnings per share were $0.06 per diluted share compared to a net income of $3.5 million and earnings per share of $0.04 in the prior year quarter. First quarter 2011 included $1.0 million in revenue and $1.1 million in net income from Akorn’s participation in the Akorn-Strides LLC joint venture. All joint venture sales activities ended on April 29, 2011 with the transfer of the remaining joint venture abbreviated new drug approvals (ANDAs) to Pfizer as previously announced on December 29, 2010. In the second quarter 2011, the Company will recognize its share of the gain on the transfer of these remaining ANDAs.

2011 Revised Outlook inclusive of impact from the pending acquisition of AVR

● The Company projects 2011 revenue in the range of $94.0 million to $98.0 million before the impact of the AVR acquisition. AVR is expected to add approximately $12.0 million to 2011 revenues. The company now projects 2011 revenues in the range of $106 million to $110 million.

● The Company’s 2011 gross margin is projected to be between 52% and 54% including the impact of the AVR acquisition.

● The Company projects 2011 adjusted EBITDA of approximately $25.0 million to $30.0 million including the impact of the AVR acquisition.

● In 2011, the Company expects to spend approximately $15 million to $20 million in capital expenditures to increase plant capacities and improve efficiencies.

● The Company is projecting 2011 R&D expenses of approximately $9.0 million to $10.0million.

● The Company’s 2011 outlook excludes the impact of any new approvals after May 2, 2011.

AKORN’S R&D PIPELINE

The Company has 20 ANDAs filed with the FDA with a combined annual market size of approximately $3.1 billion. The Company has completed development work on 10 additional products with a combined annual market size of approximately $900 million and expects to file these products with the FDA shortly.

FIRST QUARTER 2011 CONFERENCE CALL

The Company will host a conference call at 10:00 a.m. Eastern Time on Tuesday, May 3, 2011, to discuss first quarter 2011 results followed by a Q&A session. The domestic call-in number is (866) 316-1365 and the international call-in number is (913) 312-0981. The confirmation code for all callers is 2538920. The URL for the webcast is http://www.videonewswire.com/event.asp?id=78328.

About Akorn, Inc.

Akorn, Inc. is a niche pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois and Somerset, New Jersey where the Company manufactures ophthalmic and injectable pharmaceuticals. Additional information is available on the Company’s website at www.akorn.com.

Forward Looking Statement

This press release includes statements that may constitute "forward-looking statements", including projections of certain measures of Akorn's results of operations, projections of certain charges and expenses, statements regarding Akorn's goals, regulatory approvals and strategy and other statements relating to the acquisition of AVR by Akorn. Such forward looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the acquisition will be completed, or if it is completed, that it will close within the anticipated time period or that the expected benefits of the acquisition will be realized. Akorn cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of future operating or financial performance. Factors that could cause or contribute to such differences include, but are not limited to: statements relating to future steps we may take, prospective products, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. These cautionary statements should be considered in connection with any subsequent written or oral forward-looking statements that may be made by the company or by persons acting on its behalf and in conjunction with its periodic SEC filings. You are advised, however, to consult any further disclosures we make on related subjects in our reports filed with the SEC. In particular, you should read the discussion in the section entitled "Cautionary Statement Regarding Forward-Looking Statements" in our most recent Annual Report on Form 10-K, as it may be updated in subsequent reports filed with the SEC. That discussion covers certain risks, uncertainties and possibly inaccurate assumptions that could cause our actual results to differ materially from expected and historical results. Other factors besides those listed there could also adversely affect our results.

Non-GAAP Financial Measures

In addition to reporting all financial information required in accordance with generally accepted accounting principles (GAAP), Akorn is also reporting Adjusted EBITDA, which is a non-GAAP financial measure. Since Adjusted EBITDA is not a GAAP financial measure, it should not be used in isolation or as a substitute for consolidated statements of operations and cash flow data prepared in accordance with GAAP. In addition, Akorn’s definition of Adjusted EBITDA may not be comparable to similarly titled non-GAAP financial measures reported by other companies. For a full reconciliation of Adjusted EBITDA to net income, please see the attachments to this earnings release.

Adjusted EBITDA, as defined by the company, is calculated as follows:

Net income, plus:

● Interest income (expense), net

● Provision for income taxes

● Depreciation and amortization

● Non-cash expenses, such as share-based compensation expense and changes in the fair value of warrants

● Other adjustments, such as supply agreement termination expenses and equity in earnings of unconsolidated joint venture related to the sale of the joint venture's assets

The Company believes that Adjusted EBITDA is a meaningful indicator, to both Company management and investors, of the past and expected ongoing operating performance of the Company. EBITDA is a commonly used and widely accepted measure of financial performance. Adjusted EBITDA is deemed by the Company to be a useful performance indicator because it includes an add back of non-cash and non-recurring operating expenses which have little to no bearing on cash flows and may be subject to uncontrollable factors not reflective of the Company’s true operational performance (i.e. fair value adjustments to the carrying value of stock warrants liability).

While the Company uses Adjusted EBITDA in managing and analyzing its business and financial condition and believes it to be useful to investors in their evaluating the Company’s performance, Adjusted EBITDA has certain shortcomings. Specifically, Adjusted EBITDA does not take into account the impact of capital expenditures on the liquidity or GAAP financial performance of the company and likewise omits share-based compensation expenses, which may vary over time and may represent a material portion of overall compensation expense. Accordingly, the Company’s management utilizes comparable GAAP financial measures to evaluate the business in conjunction with Adjusted EBITDA and encourages investors to do likewise.

AKORN, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
IN THOUSANDS, EXCEPT PER SHARE DATA
(UNAUDITED)
	THREE MONTHS ENDED
	MARCH 31,
		2011			2010
Revenues	$	25,444		$	20,520
Cost of sales		11,191			12,092
GROSS PROFIT		14,253			8,428
Selling, general and administrative expenses		6,402			4,757
Research and development expenses		1,887			1,432
Amortization of intangibles		256			414
TOTAL OPERATING EXPENSES		8,545			6,603
OPERATING INCOME		5,708			1,825
Write-off and amortization of deferred financing costs		(193	)		(273	)
Interest income (expense), net		11			(290	)
Equity in earnings of unconsolidated joint venture		824			464
Change in fair value of warrants liability		-			1,798
INCOME BEFORE INCOME TAXES		6,350			3,524
Income tax provision		540			4
NET INCOME	$	5,810		$	3,520
NET INCOME PER SHARE:
BASIC	$	0.06		$	0.04
DILUTED	$	0.06		$	0.04
SHARES USED IN COMPUTING NET INCOME
PER SHARE:
BASIC		94,197			90,446
DILUTED		103,985			92,817

AKORN, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
IN THOUSANDS, EXCEPT SHARE DATA
	MARCH 31,			DECEMBER 31,
	2011			2010
	(Unaudited)			(Audited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	45,712		$	41,623
Trade accounts receivable, net		14,453			11,270
Inventories		19,830			18,917
Prepaid expenses and other current assets		1,810			1,803
TOTAL CURRENT ASSETS		81,805			73,613
PROPERTY, PLANT AND EQUIPMENT, NET		34,014			32,731
OTHER LONG-TERM ASSETS:
Intangibles, net		2,866			3,122
Deferred financing costs		1,352			1,545
Other		105			105
TOTAL OTHER LONG-TERM ASSETS		4,323			4,772
TOTAL ASSETS	$	120,142		$	111,116
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Trade accounts payable	$	6,477		$	4,894
Accrued compensation		1,428			3,396
Accrued expenses and other liabilities		3,763			3,473
Advance from unconsolidated joint venture		10,680			10,177
TOTAL CURRENT LIABILITIES		22,348			21,940
LONG-TERM LIABILITIES:
Lease incentive obligations		1,096			1,125
Product warranty liability		1,299			1,299
TOTAL LONG-TERM LIABILITIES		2,395			2,424
TOTAL LIABILITIES		24,743			24,364
SHAREHOLDERS' EQUITY:
Common stock, no par value -- 150,000,000 shares authorized, 94,545,555
and 93,975,334 shares issued and outstanding at March 31, 2011
and December 31, 2010, respectively		187,030			182,466
Warrants to acquire common stock		17,946			19,673
Accumulated deficit		(109,577	)		(115,387	)
TOTAL SHAREHOLDERS' EQUITY		95,399			86,752
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$	120,142		$	111,116

AKORN, INC.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
IN THOUSANDS (UNAUDITED)
	THREE MONTHS ENDED
	MARCH 31,
	2011			2010
OPERATING ACTIVITIES
Net income	$	5,810		$	3,520
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation and amortization		1,126			1,302
Write-off and amortization of deferred financing fees		193			273
Non-cash stock compensation expense		731			301
Non-cash change in fair value of warrants liability		-			(1,798	)
Equity in earnings of unconsolidated joint venture		(824	)		(464	)
Changes in operating assets and liabilities:
Trade accounts receivable		(3,183	)		(2,413	)
Inventories		(913	)		901
Prepaid expenses and other current assets		(7	)		575
Trade accounts payable		1,583			(23	)
Accrued expenses and other liabilities		(2,194	)		(209	)
NET CASH PROVIDED BY OPERATING ACTIVITIES		2,322			1,965
INVESTING ACTIVITIES
Purchases of property, plant and equipment		(2,131	)		(1,185	)
Distribution from unconsolidated joint venture		1,792			730
NET CASH USED IN INVESTING ACTIVITIES		(339	)		(455	)
FINANCING ACTIVITIES
Proceeds from exercise of stock warrants		1,727			-
Proceeds under stock option and stock purchase plans		379			95
Repayments of line of credit		-			(3,000	)
Net proceeds from common stock and warrant offering		-			2,469
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES		2,106			(436	)
INCREASE IN CASH AND CASH EQUIVALENTS		4,089			1,074
Cash and cash equivalents at beginning of period		41,623			1,617
CASH AND CASH EQUIVALENTS AT END OF PERIOD	$	45,712		$	2,691

AKORN, INC.
RECONCILIATION OF NET INCOME TO NON-GAAP ADJUSTED EBITDA
IN THOUSANDS (UNAUDITED)
	THREE MONTHS ENDED
	MARCH 31,
		2011			2010
NET INCOME	$	5,810		$	3,520
ADJUSTMENTS TO ARRIVE AT EBITDA:
Depreciation and amortization expense		1,126			1,302
Interest (income) expense, net		(11	)		290
Income tax provision		540			4
EBITDA	$	7,465		$	5,116
NON-CASH AND OTHER NON-RECURRING INCOME
AND EXPENSES:
Non-cash stock compensation expense		731			301
Change in fair value of warrants liability		-			(1,798	)
Write-off and amortization of deferred financing costs		193			273
ADJUSTED EBITDA	$	8,389		$	3,892

CONTACT:

At the Company:

Akorn, Inc.

Tim Dick, Chief Financial Officer

(847) 279-6150

EX-9.2

Exhibit 99.2

Akorn Enters Into an Agreement to Acquire Advanced Vision Research

-Expands Presence in the $1.2 billion Over-the-Counter Eye Care Market-

LAKE FOREST, Ill.--(BUSINESS WIRE)--May 3, 2011--Akorn, Inc. (NASDAQ:AKRX), a niche generic pharmaceutical company, announced today that it has entered into an agreement to acquire Woburn, MA, based Advanced Vision Research, Inc. (“AVR”), a premier over-the-counter (“OTC”) ophthalmic company that develops and markets eye care products under the TheraTears® and MacuTrition® brand names, for $26 million in cash on hand. These products are used for dry eyes, eyelid hygiene, contact lens comfort and eye nutrition. AVR was founded in 1995 by the late Jeffery P. Gilbard, M.D. with its lead products developed in the clinics and laboratories of Harvard University’s Schepens Eye Research Institute. In 2010, AVR generated sales of $20 million, which consisted of domestic sales through major retail chains and sales in 20 countries across 5 continents.

Akorn also announced plans to launch a new Consumer Health Division to enter the $1.2 billion OTC eye care market, pending the acquisition of AVR. The company plans to further expand by licensing new products and developing private labeled eye care products for major retailers. The company named Bruce Kutinsky, Pharm. D., as its President of the newly formed Consumer Health Division. Mr. Kutinsky joined Akorn as its Senior Vice President of Corporate Strategy in 2010. Prior to joining Akorn, Mr. Kutinsky served as the Vice President of Strategic Solutions at Walgreens. Mr. Kutinsky held various senior management positions at Option Care, Inc., which was acquired by Walgreens in 2007. Mr. Kutinsky started his career as a retail pharmacist and has a doctor of pharmacy degree from the University of Michigan, Ann Arbor, MI.

Raj Rai, Chief Executive Officer commented, “AVR is a great strategic platform to expand into the OTC eye care market. We have had a positive relationship with AVR for several years as a primary contract manufacturer. With the acquisition, we can add value in future growth as we have an existing sales infrastructure that markets products to ophthalmologists, optometrists, and retailers nationwide complementing AVR’s sales initiatives.”

The Company expects the AVR acquisition to be neutral to its 2011 earnings per share after the impact of transaction related expenses and the impact of purchase price allocation of $.01 to $.02 in earnings per share. In 2012, AVR is expected to be accretive by $.03 to $.04 earnings per share.

About Akorn, Inc.

Akorn, Inc. is a niche pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois and Somerset, New Jersey where the Company manufactures ophthalmic and injectable pharmaceuticals. Additional information is available on the Company’s website at www.akorn.com.

Forward Looking Statement

This press release includes statements that may constitute "forward-looking statements", including projections of certain measures of Akorn's results of operations, projections of certain charges and expenses, statements regarding Akorn's goals, regulatory approvals and strategy, and other statements relating to the acquisition of AVR by Akorn. Such forward looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the acquisition will be completed, or if it is completed, that it will close within the anticipated time period or that the expected benefits of the acquisition will be realized. Akorn cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of future operating or financial performance. Factors that could cause or contribute to such differences include, but are not limited to: statements relating to future steps we may take, prospective products, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. These cautionary statements should be considered in connection with any subsequent written or oral forward-looking statements that may be made by the company or by persons acting on its behalf and in conjunction with its periodic SEC filings. You are advised, however, to consult any further disclosures we make on related subjects in our reports filed with the SEC. In particular, you should read the discussion in the section entitled "Cautionary Statement Regarding Forward-Looking Statements" in our most recent Annual Report on Form 10-K, as it may be updated in subsequent reports filed with the SEC. That discussion covers certain risks, uncertainties and possibly inaccurate assumptions that could cause our actual results to differ materially from expected and historical results. Other factors besides those listed there could also adversely affect our results.

CONTACT:

Akorn, Inc.

Tim Dick, 847-279-6150

Chief Financial Officer